Listed by the USPTO as ZOU, NIANXIANG
Tech Center 1600 • Art Units: 1600 1642 1648 1671 1675
This examiner grants 64% of resolved cases
ZOU, NIANXIANG works in Tech Center 1600 and Art Unit 1600. The profile reports 781 resolved cases and an allowance rate of 64.0%. The median time to allowance is 994 days, so applicants should incorporate a substantial prosecution interval into filing and portfolio decisions.
The interview lift is 25.0%, indicating a meaningful association with allowance outcomes. An interview may help focus the examiner’s concerns and guide the written response, particularly when technical distinctions require explanation. The represented organizations include Laboratory Corporation of America Holdings, Takeda Pharmaceutical Company Limited, and University of Florida Research Foundation Inc. The listed firms are BOZICEVIC, FIELD & FRANCIS LLP, ArentFox Schiff, LLP & Memorial Sloan-Kettering, and BakerHostetler - Inovio.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17800687 | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18847937 | METHODS AND COMPOSITIONS FOR PURIFYING ADENO ASSOCIATED VIRUS PARTICLES | Non-Final OA | MERCK PATENT GMBH |
| 18344952 | METHODS FOR DETERMINING SARS-COV-2 ANTIGEN AND ANTI-SARS-COV-2 ANTIBODY IN A SAMPLE | Final Rejection | Abbott Laboratories |
| 18560515 | Coronavirus Constructs and Vaccines | Non-Final OA | The Regents of the University of California |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18520057 | E1E2 HCV VACCINES AND METHODS OF USE | Final Rejection | The Governors of the University of Alberta |
| 18883669 | Compositions For and Methods of Treating Influenza | Non-Final OA | President and Fellows of Harvard College |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | Non-Final OA | PFIZER INC. |
| 18415814 | METHOD OF DETECTING SARS-COV IN A SAMPLE | Final Rejection | Imam Abdulrahman Bin Faisal University |
| 18835922 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | Non-Final OA | Takeda Vaccines, Inc. |
| 18030647 | METHODS FOR DETERMINING COMPLEMENT-FIXING ANTIBODIES | Final Rejection | TAKEDA VACCINES, INC. |
| 18229072 | SAMPLE PRETREATMENT KIT AND METHOD FOR DETECTING VIRUS INFECTIVITY | Final Rejection | Delta Electronics Int’l (Singapore) Pte Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy64.0% of resolved applications examined by Nianxiang Zou were allowed (781 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +25.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nianxiang Zou took 994 days on average from filing to allowance.
Nianxiang Zou examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
